Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 10/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885074 | 0.77 | KDM4E (0.62) | KDM4ETBXAS1NAPRTFDPSLMNA | |
| SCHEMBL5041945 | 0.77 | FDPS (0.47) | KDM4ETBXAS1NAPRTFDPSLMNA | |
| SCHEMBL4477889 | 0.76 | TBXAS1 (0.52) | KDM4ETBXAS1NAPRTFDPSLMNA | |
| SCHEMBL5037275 | 0.75 | PPARA (0.46) | KMT2AUSP2 | |
| SCHEMBL3949678 | 0.75 | MMP8 (0.54) | KDM4ETBXAS1NAPRTFDPSLMNA | |
| SCHEMBL27041606 | 0.74 | KDM4E (0.53) | KDM4ETBXAS1NAPRTFDPSLMNA | |
| SCHEMBL27041597 | 0.74 | KDM4E (0.53) | KDM4ETBXAS1NAPRTFDPSLMNA | |
| SCHEMBL2565141 | 0.71 | TBXAS1 (0.56) | KDM4ETBXAS1NAPRTFDPSLMNA | |
| SCHEMBL6428052 | 0.71 | FDPS (0.49) | KDM4ETBXAS1NAPRTFDPS | |
| SCHEMBL7384333 | 0.69 | CYP1A2 (0.62) | KDM4ETBXAS1NAPRTFDPSLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805136-A1 | SUBSTITUTED PHENYLALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006050097-A1 | SUBSTITUTED PHENYLALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2006-05-11 | — | — | WO | claimed |
| US-20060100251-A1 | Substituted phenylalkanoic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC | 2006-05-11 | — | — | US | claimed |
| EP-1633354-B1 | N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES | INST FOR PHARM DISCOVERY INC (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1805136-A1 | SUBSTITUTED PHENYLALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006050097-A1 | SUBSTITUTED PHENYLALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060100251-A1 | Substituted phenylalkanoic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC | 2006-05-11 | — | — | US | disclosed |
| EP-1633354-A2 | N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20040248937-A1 | Substituted phenylalkanoic acids for the treatment of diabetes | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2004-12-09 | — | — | US | disclosed |
| WO-2004092146-A2 | N- (((((1,3-THIAZOL-2-YL) AMINO) CARBONYL) PHENYL) SULFONYL) PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248937-A1 | Substituted phenylalkanoic acids for the treatment of diabetes | PTP4A1, PTPRJ, PPM1B | KDM4E 1445/4885TBXAS1 2513/4885NAPRT 1601/4885 |
| US-20060100251-A1 | Substituted phenylalkanoic acids | PTPRJ, PTP4A1, PTPN1 | KDM4E 1607/4885TBXAS1 2879/4885NAPRT 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.